
## **ARCUS OVERVIEW**

**NYSE: RCUS** 



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer



#### HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



**Targets:** CD73, HIF-2α, A2α/2b, AXL



Targets: TIGIT, PD-1, CD39

Goal of 1-2

new molecules advancing into clinic each year




Accelerated

P 1/2 signalseeking & platform studies


#### **DIVERSE PIPELINE & KEY DATA FOR 2025+**


7

Different molecules in clinic St Pivotal Readout



3+ HIF-2a Cas Events





 Planned initiation of Phase 3 cas + cabo study \$10B+



Addressable market opportunity in the U.S. based on expected drug treatable patient population

### **TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS**



Funding:

~\$1.7B

- Holds ~33% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.

TAIHO PHARMA



# STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING INTO 2027



**\$1.1B** cash, cash equivalents & marketable securities as of 9/30/24

HQ & RESEARCH CAMPUSES IN BAY AREA



~600

emplovees

Except as stated otherwise, this summary is provided as of 11/6/24. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding into 2027, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com.

